About Abcepta
Abcepta is a company based in San Diego (United States) founded in 2001. It operates as a B2B. Abcepta operates in a competitive market with competitors including Abcam, Stem Cell Technologies, Meridian Bioscience, Teknova and Sangon Biotech, among others.
- Headquarter San Diego, United States
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website abcepta.com
Competitors of Abcepta
Abcepta operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abcam, Stem Cell Technologies, Meridian Bioscience, Teknova and Sangon Biotech, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| abcam.com | 1998 | Cambridge, United Kingdom | $78.8M | 405 | Biological reagents and antibodies are developed for life science research. | |
| stemcell.com | 1993 | Vancouver, Canada | $11.92M | 129 | Developer of cell culture media and ancillary reagents for life science research | |
| meridianbioscience.com | 1976 | Ohio, United States | – | – | Molecular diagnostic device and kits | |
| teknova.com | 1996 | Hollister, United States | – | 290 | Molecular biology reagents and kits are supplied for research applications. | |
| sangon.com | 2003 | Shanghai, China | $300M | – | Research services, reagents, and kits for biotech applications are provided. | |
| caymanchem.com | 1980 | Ann Arbor, United States | – | 309 | Bioreagents and assay kits are developed, with preclinical services provided. | |
| bbisolutions.com | 1986 | Crumlin, United Kingdom | – | 301 | Kits and reagents are developed for life science research applications. | |
| biochain.com | 1994 | Hayward, United States | $7.34M | 24 | Provider of products and services for clinical diagnosis, genomics, and proteomics | |
| pl-bioscience.com | 2015 | Aachen, Germany | $13.03M | 13 | Cell culture solutions for stem cell expansion are provided. |
Detailed competitors of Abcepta
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Abcepta
Websites that share an audience with Abcepta (abcepta.com).
Websites whose visitors overlap most with Abcepta. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| absoluteantibody.com | 100% | 34.2K | #944,741 | View details | |
| proteogenix.science | 76% | 26.4K | #984,622 | View details |
Similar companies to Abcepta
10 companies that operate in the same segment as Abcepta (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Abcepta
Abcepta was founded in 2001.
Abcepta is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Abcepta, established in 2001, excels in providing healthcare solutions, advancing biotech innovations, antibody development, and peptide services. Provides antibody and peptide development services. Committed to advancing standards, it focuses on innovation, efficiency, and delivering value to clients worldwide. It continues to evolve, meeting industry challenges with strategic approaches.
Abcepta's top competitors include Abcam, Meridian Bioscience and Stem Cell Technologies.